Jiyeon Ock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiyeon Ock has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Guo Nan Yin
Department of Urology and National Research Center for Sexual Medicine, Inha University School of Medicine, Incheon, Republic of Korea
10 shared publications - Ji-Kan Ryu
Department of Urology and National Research Center for Sexual Medicine, Inha University School of Medicine, Incheon, Republic of Korea
10 shared publications - Jun-Kyu Suh
National Research Center for Sexual Medicine and Department of Urolog, Inha University School of Medicine
8 shared publications - Min Ji Choi
National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon, Korea
6 shared publications - Anita Limanjaya
National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon, Korea
5 shared publications - Kalyan Ghatak
National Research Center for Sexual Medicine and Department of Urology, Inha University School of Medicine, Incheon, Korea
5 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by XMLink in Investigative and Clinical Urology
- Vol. 66 (1) , 74-86
Ablation of IGFBP5 expression alleviates neurogenic erectile dysfunction by inducing neurovascular regeneration
Ock J, et al. Investig Clin Urol. 2025 Jan;66(1):74-86. https://doi.org/10.4111/icu.20240325
- 1 January 2025
- Published by XMLink in Investigative and Clinical Urology
- Vol. 66 (1) , 74-86
Open AccessAblation of IGFBP5 expression alleviates neurogenic erectile dysfunction by inducing neurovascular regeneration
Ock J, et al. Investig Clin Urol. 2025 Jan;66(1):74-86. https://doi.org/10.4111/icu.20240325
- Open Access
- 3 May 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 12
Single cell transcriptome analysis of cavernous tissues reveals the key roles of pericytes in diabetic erectile dysfunction
Erectile dysfunction (ED) affects a significant proportion of men aged 40–70 and is caused by cavernous tissue dysfunction. Presently, the most common treatment for ED is phosphodiesterase 5 inhibitors; however, this is less effective in patients with severe vascular disease such as diabetic ED. Therefore, there is a need for development of new treatment, which requires a better understanding of the cavernous microenvironment and cell-cell communications under diabetic condition. Pericytes are vital in penile erection; however, their dysfunction due to diabetes remains unclear. In this study, we performed single-cell RNA sequencing to understand the cellular landscape of cavernous tissues and cell type-specific transcriptional changes in diabetic ED. We found a decreased expression of genes associated with collagen or extracellular matrix organization and angiogenesis in diabetic fibroblasts, chondrocytes, myofibroblasts, valve-related lymphatic endothelial cells, and pericytes. Moreover, the newly identified pericyte-specific marker, Limb Bud-Heart (Lbh), in mouse and human cavernous tissues, clearly distinguishing pericytes from smooth muscle cells. Cell–cell interaction analysis revealed that pericytes are involved in angiogenesis, adhesion, and migration by communicating with other cell types in the corpus cavernosum; however, these interactions were highly reduced under diabetic conditions. Lbh expression is low in diabetic pericytes, and overexpression of LBH prevents erectile function by regulating neurovascular regeneration. Furthermore, the LBH-interacting proteins (Crystallin Alpha B and Vimentin) were identified in mouse cavernous pericytes through LC-MS/MS analysis, indicating that their interactions were critical for maintaining pericyte function. Thus, our study reveals novel targets and insights into the pathogenesis of ED in patients with diabetes.
- 3 May 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 12
Open AccessSingle cell transcriptome analysis of cavernous tissues reveals the key roles of pericytes in diabetic erectile dysfunction
Erectile dysfunction (ED) affects a significant proportion of men aged 40–70 and is caused by cavernous tissue dysfunction. Presently, the most common treatment for ED is phosphodiesterase 5 inhibitors; however, this is less effective in patients with severe vascular disease such as diabetic ED. Therefore, there is a need for development of new treatment, which requires a better understanding of the cavernous microenvironment and cell-cell communications under diabetic condition. Pericytes are vital in penile erection; however, their dysfunction due to diabetes remains unclear. In this study, we performed single-cell RNA sequencing to understand the cellular landscape of cavernous tissues and cell type-specific transcriptional changes in diabetic ED. We found a decreased expression of genes associated with collagen or extracellular matrix organization and angiogenesis in diabetic fibroblasts, chondrocytes, myofibroblasts, valve-related lymphatic endothelial cells, and pericytes. Moreover, the newly identified pericyte-specific marker, Limb Bud-Heart (Lbh), in mouse and human cavernous tissues, clearly distinguishing pericytes from smooth muscle cells. Cell–cell interaction analysis revealed that pericytes are involved in angiogenesis, adhesion, and migration by communicating with other cell types in the corpus cavernosum; however, these interactions were highly reduced under diabetic conditions. Lbh expression is low in diabetic pericytes, and overexpression of LBH prevents erectile function by regulating neurovascular regeneration. Furthermore, the LBH-interacting proteins (Crystallin Alpha B and Vimentin) were identified in mouse cavernous pericytes through LC-MS/MS analysis, indicating that their interactions were critical for maintaining pericyte function. Thus, our study reveals novel targets and insights into the pathogenesis of ED in patients with diabetes.
- Open Access
- 1 January 2024
- Published by XMLink in The World Journal of Men's Health
- Vol. 42 (4) , 842-854
Photobiomodulation as a Potential Therapy for Erectile Function: A Preclinical Study in a Cavernous Nerve Injury Model
Anita L, et al. World J Mens Health. 2024 Apr;42:e48. https://doi.org/10.5534/wjmh.230187
- 1 January 2024
- Published by XMLink in The World Journal of Men's Health
- Vol. 42 (4) , 842-854
Open AccessPhotobiomodulation as a Potential Therapy for Erectile Function: A Preclinical Study in a Cavernous Nerve Injury Model
Anita L, et al. World J Mens Health. 2024 Apr;42:e48. https://doi.org/10.5534/wjmh.230187
- Open Access
Single cell transcriptome analysis of cavernous tissues reveals the key roles of pericytes in diabetic erectile dysfunction
Erectile dysfunction (ED) affects a significant proportion of men aged 40–70 and is caused by cavernous tissue dysfunction. Presently, the most common treatment for ED is phosphodiesterase 5 inhibitors; however, this is less effective in patients with severe vascular disease such as diabetic ED. Therefore, there is a need for development of new treatment, which requires a better understanding of the cavernous microenvironment and cell-cell communications under diabetic condition. Pericytes are vital in penile erection; however, their dysfunction due to diabetes remains unclear. In this study, we performed single-cell RNA sequencing to understand the cellular landscape of cavernous tissues and cell type-specific transcriptional changes in diabetic ED. We found a decreased expression of genes associated with collagen or extracellular matrix organization and angiogenesis in diabetic fibroblasts, chondrocytes, myofibroblasts, valve-related lymphatic endothelial cells, and pericytes. Moreover, the newly identified pericyte-specific marker, Limb-bud and Heart (Lbh), in mouse and human cavernous tissues, clearly distinguishing pericytes from smooth muscle cells. Cell–cell interaction analysis revealed that pericytes are involved in angiogenesis, adhesion, and migration by communicating with other cell types in the corpus cavernosum; however, these interactions were highly reduced under diabetic conditions. Lbh expression is low in diabetic pericytes, and overexpression of LBH prevents erectile function by regulating neurovascular regeneration. Furthermore, the LBH-interacting proteins (Crystallin Alpha B and Vimentin) were identified in mouse cavernous pericytes through LC-MS/MS analysis, indicating that their interactions were critical for maintaining pericyte function. Thus, our study reveals novel targets and insights into the pathogenesis of ED in patients with diabetes. Impact statement: Single-cell RNA sequencing analysis of diabetic mouse cavernous tissue revealed that LBH as a novel pericyte marker and may interact with Crystallin Alpha B and Vimentin to promote neurovascular regeneration.
Open AccessSingle cell transcriptome analysis of cavernous tissues reveals the key roles of pericytes in diabetic erectile dysfunction
Erectile dysfunction (ED) affects a significant proportion of men aged 40–70 and is caused by cavernous tissue dysfunction. Presently, the most common treatment for ED is phosphodiesterase 5 inhibitors; however, this is less effective in patients with severe vascular disease such as diabetic ED. Therefore, there is a need for development of new treatment, which requires a better understanding of the cavernous microenvironment and cell-cell communications under diabetic condition. Pericytes are vital in penile erection; however, their dysfunction due to diabetes remains unclear. In this study, we performed single-cell RNA sequencing to understand the cellular landscape of cavernous tissues and cell type-specific transcriptional changes in diabetic ED. We found a decreased expression of genes associated with collagen or extracellular matrix organization and angiogenesis in diabetic fibroblasts, chondrocytes, myofibroblasts, valve-related lymphatic endothelial cells, and pericytes. Moreover, the newly identified pericyte-specific marker, Limb-bud and Heart (Lbh), in mouse and human cavernous tissues, clearly distinguishing pericytes from smooth muscle cells. Cell–cell interaction analysis revealed that pericytes are involved in angiogenesis, adhesion, and migration by communicating with other cell types in the corpus cavernosum; however, these interactions were highly reduced under diabetic conditions. Lbh expression is low in diabetic pericytes, and overexpression of LBH prevents erectile function by regulating neurovascular regeneration. Furthermore, the LBH-interacting proteins (Crystallin Alpha B and Vimentin) were identified in mouse cavernous pericytes through LC-MS/MS analysis, indicating that their interactions were critical for maintaining pericyte function. Thus, our study reveals novel targets and insights into the pathogenesis of ED in patients with diabetes. Impact statement: Single-cell RNA sequencing analysis of diabetic mouse cavernous tissue revealed that LBH as a novel pericyte marker and may interact with Crystallin Alpha B and Vimentin to promote neurovascular regeneration.
- Open Access
IGFBP5 antisense and short hairpin RNA (shRNA) constructs improve erectile function by inducing cavernosum angiogenesis in diabetic mice
Background: The incidence of diabetic erectile dysfunction (ED) is rapidly increasing, and due to the severe angiopathy caused by diabetes, current drugs are ineffective at treating ED. Insulin‐like growth factor‐binding protein 5 (IGFBP5) promotes cell death and induces apoptosis in various cell types.Objectives: To evaluate the effectiveness of IGFBP5 knockdown in improving erectile function in diabetic mice.Materials and methods: Diabetes was induced by injecting streptozotocin (STZ) intraperitoneally into male 8‐week‐old C57BL/6 mice. Eight weeks after diabetes induction, mice were divided into four groups: a nondiabetic control group and three STZ‐induced diabetic mice groups, which were administered intracavernous injections of phosphate buffered saline, scrambled control shRNA, or shRNA targeting mouse IGFBP5 (shIGFBP5) lentivirus particles. Two weeks later, we measured erectile function by electrically stimulating the bilateral cavernous nerve. To mimic diabetic angiopathy, primary cavernous endothelial cells (MCECs) from healthy mice were cultured and treated with glucose.Results: IGFBP5 expression in MCECs or cavernous tissues were significantly increased under diabetic conditions, and knockdown of IGFBP5 induced MCECs angiogenic activity under high‐glucose conditions. STZ‐induced diabetic mice had reduced erectile function, but shIGFBP5 treatment resulted in significant improvements (to 90% of the nondiabetic control group level). Furthermore, in diabetic mice, numbers of cavernous endothelial cells, pericytes, and neuronal cells were increased by shIGFBP5 treatment, which also increased eNOS Ser1177 phosphorylation, decreased permeability and apoptosis of cavernous endothelial cells. In addition, IGFBP5 was found to mediate the AKT, ERK, p38 signaling pathways.Discussion and conclusion: Knockdown of IGFBP5 improved erectile function in diabetic mice by promoting cell proliferation and reducing apoptosis and permeability. Local inhibition of IGFBP5 expression may provide a new treatment strategy for diabetic ED and other ischemic vascular or neurological diseases.
Open AccessIGFBP5 antisense and short hairpin RNA (shRNA) constructs improve erectile function by inducing cavernosum angiogenesis in diabetic mice
Background: The incidence of diabetic erectile dysfunction (ED) is rapidly increasing, and due to the severe angiopathy caused by diabetes, current drugs are ineffective at treating ED. Insulin‐like growth factor‐binding protein 5 (IGFBP5) promotes cell death and induces apoptosis in various cell types.Objectives: To evaluate the effectiveness of IGFBP5 knockdown in improving erectile function in diabetic mice.Materials and methods: Diabetes was induced by injecting streptozotocin (STZ) intraperitoneally into male 8‐week‐old C57BL/6 mice. Eight weeks after diabetes induction, mice were divided into four groups: a nondiabetic control group and three STZ‐induced diabetic mice groups, which were administered intracavernous injections of phosphate buffered saline, scrambled control shRNA, or shRNA targeting mouse IGFBP5 (shIGFBP5) lentivirus particles. Two weeks later, we measured erectile function by electrically stimulating the bilateral cavernous nerve. To mimic diabetic angiopathy, primary cavernous endothelial cells (MCECs) from healthy mice were cultured and treated with glucose.Results: IGFBP5 expression in MCECs or cavernous tissues were significantly increased under diabetic conditions, and knockdown of IGFBP5 induced MCECs angiogenic activity under high‐glucose conditions. STZ‐induced diabetic mice had reduced erectile function, but shIGFBP5 treatment resulted in significant improvements (to 90% of the nondiabetic control group level). Furthermore, in diabetic mice, numbers of cavernous endothelial cells, pericytes, and neuronal cells were increased by shIGFBP5 treatment, which also increased eNOS Ser1177 phosphorylation, decreased permeability and apoptosis of cavernous endothelial cells. In addition, IGFBP5 was found to mediate the AKT, ERK, p38 signaling pathways.Discussion and conclusion: Knockdown of IGFBP5 improved erectile function in diabetic mice by promoting cell proliferation and reducing apoptosis and permeability. Local inhibition of IGFBP5 expression may provide a new treatment strategy for diabetic ED and other ischemic vascular or neurological diseases.
- Open Access
- 1 January 2021
- Published by XMLink in Investigative and Clinical Urology
- Vol. 62 (1) , 90-99
Gene expression profiling of mouse cavernous endothelial cells for diagnostic targets in diabetes-induced erectile dysfunction
Yin GN, et al. Investig Clin Urol. 2021 Jan;62(1):90-99. https://doi.org/10.4111/icu.20200119
- 1 January 2021
- Published by XMLink in Investigative and Clinical Urology
- Vol. 62 (1) , 90-99
Open AccessGene expression profiling of mouse cavernous endothelial cells for diagnostic targets in diabetes-induced erectile dysfunction
Yin GN, et al. Investig Clin Urol. 2021 Jan;62(1):90-99. https://doi.org/10.4111/icu.20200119
- Open Access
- 1 January 2021
- Published by Korean Society for Sexual Medicine and Andrology in The World Journal of Men's Health
- Vol. 39 (1) , 131-138
Three-Dimensional Reconstruction of Neurovascular Network in Whole Mount Preparations and Thick-Cut Transverse Sections of Mouse Urinary Bladder
Nguyen NM, et al. World J Mens Health. 2021 Jan;39(1):131-138. https://doi.org/10.5534/wjmh.190089
- 1 January 2021
- Published by Korean Society for Sexual Medicine and Andrology in The World Journal of Men's Health
- Vol. 39 (1) , 131-138
Open AccessThree-Dimensional Reconstruction of Neurovascular Network in Whole Mount Preparations and Thick-Cut Transverse Sections of Mouse Urinary Bladder
Nguyen NM, et al. World J Mens Health. 2021 Jan;39(1):131-138. https://doi.org/10.5534/wjmh.190089
Neutralizing antibody to proNGF rescues erectile function by regulating the expression of neurotrophic and angiogenic factors in a mouse model of cavernous nerve injury
Background: Radical prostatectomy induces some degree of cavernous nerve injury (CNI) and causes denervation‐induced pathologic changes in cavernous vasculature, regardless of the advances in surgical techniques and robotic procedures. The precursor for nerve growth factor (proNGF) is known to be involved in neuronal cell apoptosis and microvascular dysfunction through its receptor p75NTR.Objectives: To determine the expression of proNGF/p75NTR and the efficacy of proNGF neutralizing antibody (anti‐proNGF‐Ab) in a mouse model of ED induced by CNI.Materials and Methods: Age‐matched 12‐week‐old C57BL/6 mice were distributed into three groups: sham group and bilateral CNI group treated with intracavernous injections of PBS (20 μL) or of anti‐proNGF‐Ab (20 µg in 20 μL of PBS) on days −3 and 0. Two weeks after treatment, erectile function was measured by electrical stimulation of cavernous nerve. Penis tissues from a separate group of animals were harvested for further analysis. We also determined the efficacy of anti‐proNGF‐Ab on neural preservation in major pelvic ganglion (MPG) ex vivo.Results: We observed increased penile expression of proNGF and p75NTR after CNI. Intracavernous administration of anti‐proNGF‐Ab increased nNOS and neurofilament expression probably by enhancing the production of neurotrophic factors, such as neurotrophin‐3, NGF, and brain‐derived neurotrophic factor. Anti‐proNGF‐Ab preserved the integrity of cavernous sinusoids, such as pericytes, endothelial cells, and endothelial cell‐to‐cell junctions, possibly by controlling angiogenic factors (angiopoietin‐1, angiopoietin‐2, and vascular endothelial growth factor) and induced endogenous eNOS phosphorylation in CNI mice. And finally, treatment with anti‐proNGF‐Ab rescued erectile function in CNI mice. Anti‐proNGF‐Ab also enhanced neurite sprouting from MPG exposed to lipopolysaccharide.Discussion and Conclusion: The preservation of damaged cavernous neurovasculature through inhibition of the proNGF/p75NTR pathway may be a novel strategy to treat radical prostatectomy‐induced erectile dysfunction.
Neutralizing antibody to proNGF rescues erectile function by regulating the expression of neurotrophic and angiogenic factors in a mouse model of cavernous nerve injury
Background: Radical prostatectomy induces some degree of cavernous nerve injury (CNI) and causes denervation‐induced pathologic changes in cavernous vasculature, regardless of the advances in surgical techniques and robotic procedures. The precursor for nerve growth factor (proNGF) is known to be involved in neuronal cell apoptosis and microvascular dysfunction through its receptor p75NTR.Objectives: To determine the expression of proNGF/p75NTR and the efficacy of proNGF neutralizing antibody (anti‐proNGF‐Ab) in a mouse model of ED induced by CNI.Materials and Methods: Age‐matched 12‐week‐old C57BL/6 mice were distributed into three groups: sham group and bilateral CNI group treated with intracavernous injections of PBS (20 μL) or of anti‐proNGF‐Ab (20 µg in 20 μL of PBS) on days −3 and 0. Two weeks after treatment, erectile function was measured by electrical stimulation of cavernous nerve. Penis tissues from a separate group of animals were harvested for further analysis. We also determined the efficacy of anti‐proNGF‐Ab on neural preservation in major pelvic ganglion (MPG) ex vivo.Results: We observed increased penile expression of proNGF and p75NTR after CNI. Intracavernous administration of anti‐proNGF‐Ab increased nNOS and neurofilament expression probably by enhancing the production of neurotrophic factors, such as neurotrophin‐3, NGF, and brain‐derived neurotrophic factor. Anti‐proNGF‐Ab preserved the integrity of cavernous sinusoids, such as pericytes, endothelial cells, and endothelial cell‐to‐cell junctions, possibly by controlling angiogenic factors (angiopoietin‐1, angiopoietin‐2, and vascular endothelial growth factor) and induced endogenous eNOS phosphorylation in CNI mice. And finally, treatment with anti‐proNGF‐Ab rescued erectile function in CNI mice. Anti‐proNGF‐Ab also enhanced neurite sprouting from MPG exposed to lipopolysaccharide.Discussion and Conclusion: The preservation of damaged cavernous neurovasculature through inhibition of the proNGF/p75NTR pathway may be a novel strategy to treat radical prostatectomy‐induced erectile dysfunction.
- Open Access
- 1 January 2020
- Published by XMLink in The World Journal of Men's Health
- Vol. 38 (4) , 552-563
Vactosertib, a Novel, Orally Bioavailable Activin Receptor-Like Kinase 5 Inhibitor, Promotes Regression of Fibrotic Plaques in a Rat Model of Peyronie's Disease
Song KM, et al. World J Mens Health. 2019 Jan;37:e50. https://doi.org/10.5534/wjmh.190071
- 1 January 2020
- Published by XMLink in The World Journal of Men's Health
- Vol. 38 (4) , 552-563
Open AccessVactosertib, a Novel, Orally Bioavailable Activin Receptor-Like Kinase 5 Inhibitor, Promotes Regression of Fibrotic Plaques in a Rat Model of Peyronie's Disease
Song KM, et al. World J Mens Health. 2019 Jan;37:e50. https://doi.org/10.5534/wjmh.190071
- Open Access
- 1 January 2020
- Published by Korean Society for Sexual Medicine and Andrology in The World Journal of Men's Health
- Vol. 38 (1) , 123-131
A Simple and Nonenzymatic Method to Isolate Human Corpus Cavernosum Endothelial Cells and Pericytes for the Study of Erectile Dysfunction
To establish a simple and nonenzymatic technique to isolate endothelial cells (ECs) and pericytes from human corpus cavernosum tissue and to evaluate the angiogenic ability of the human cavernous EC or pericytes for the study of high glucose-induced angiopathy. For primary human cavernous EC culture, cavernous tissues were implanted into Matrigel in dishes. For primary human cavernous pericyte culture, cavernous tissues were settled by gravity into dishes. We performed immunocytochemistry and Western blot to determine phenotype and morphologic changes from passage 1 to 5. The primary cultured cells were exposed to a normal-glucose (5 mmol/L) or a high-glucose (30 mmol/L) condition, and then tube formation assay was done. We successfully isolated high-purity EC and pericytes from human corpus cavernosum tissue. Primary cultured EC showed highly positive staining for von Willebrand factor, and pericyte revealed positive staining for NG2 and platelet-derived growth factor receptor-β. Primary cultured EC and pericytes maintained their cellular characteristics up to passage 2 or 3. However, we observed significant changes in their typical phenotype from the passage 4 and morphological characteristics from the passage 3. Human cavernous EC or pericytes formed well-organized capillary-like structures in normal-glucose condition, whereas severely impaired tube formation was detected in high-glucose condition. This study provides a simple and nonenzymatic method for primary culture of human cavernous EC and pericytes. Our study will aid us to understand the pathophysiology of diabetic erectile dysfunction, and also be a valuable tool for determining the efficacy of candidate therapeutic targets.
- 1 January 2020
- Published by Korean Society for Sexual Medicine and Andrology in The World Journal of Men's Health
- Vol. 38 (1) , 123-131
Open AccessA Simple and Nonenzymatic Method to Isolate Human Corpus Cavernosum Endothelial Cells and Pericytes for the Study of Erectile Dysfunction
To establish a simple and nonenzymatic technique to isolate endothelial cells (ECs) and pericytes from human corpus cavernosum tissue and to evaluate the angiogenic ability of the human cavernous EC or pericytes for the study of high glucose-induced angiopathy. For primary human cavernous EC culture, cavernous tissues were implanted into Matrigel in dishes. For primary human cavernous pericyte culture, cavernous tissues were settled by gravity into dishes. We performed immunocytochemistry and Western blot to determine phenotype and morphologic changes from passage 1 to 5. The primary cultured cells were exposed to a normal-glucose (5 mmol/L) or a high-glucose (30 mmol/L) condition, and then tube formation assay was done. We successfully isolated high-purity EC and pericytes from human corpus cavernosum tissue. Primary cultured EC showed highly positive staining for von Willebrand factor, and pericyte revealed positive staining for NG2 and platelet-derived growth factor receptor-β. Primary cultured EC and pericytes maintained their cellular characteristics up to passage 2 or 3. However, we observed significant changes in their typical phenotype from the passage 4 and morphological characteristics from the passage 3. Human cavernous EC or pericytes formed well-organized capillary-like structures in normal-glucose condition, whereas severely impaired tube formation was detected in high-glucose condition. This study provides a simple and nonenzymatic method for primary culture of human cavernous EC and pericytes. Our study will aid us to understand the pathophysiology of diabetic erectile dysfunction, and also be a valuable tool for determining the efficacy of candidate therapeutic targets.